Mayne Pharma Group (MAYNF) Stock Price, News & Analysis

Company Overview

Mayne Pharma Group (OTCMKTS:MAYNF) is a specialty pharmaceutical company focused on the development, manufacturing and commercialization of prescription products. The company’s portfolio spans oral, transdermal and topical dosage forms, with a particular emphasis on women’s health, dermatology, pain management and other niche therapeutic areas. Through both branded and generic offerings, Mayne Pharma seeks to address unmet patient needs and provide cost-effective alternatives to established treatments.

In its development operations, Mayne Pharma leverages a combination of in-house research and external partnerships to advance product candidates through regulatory review. The company operates multiple manufacturing sites across Australia, the United States and the United Kingdom, enabling end-to-end production from active pharmaceutical ingredient (API) synthesis to finished-dose packaging. This integrated model supports tight quality controls and flexible scale-up for both its own products and those made under contract for third-party clients.

Mayne Pharma’s contract development and manufacturing organization (CDMO) provides development services, commercial manufacturing and packaging solutions to global pharmaceutical and biotechnology companies. By offering a range of formulation technologies—such as film-coating, transdermal adhesives and semi-solid topical systems—the company addresses complex product requirements and accelerates time to market for partners.

Since its spin-off from a larger Australian healthcare group in the early 2000s, Mayne Pharma has grown through a combination of organic investment and strategic acquisitions, expanding its presence in key markets. Headquartered in Melbourne with a significant commercial office in Raleigh, North Carolina, the company is led by Chief Executive Officer Scott Richards. Mayne Pharma continues to pursue a balanced strategy of strengthening its specialty pharmaceutical pipeline while supporting external clients through its CDMO capabilities.

Key Stats

• Today's Range: $1.65 to $1.65
• 50-Day Range: $1.40 to $1.81
• 52-Week Range: $1.40 to $4.00
• Volume: N/A
• Average Volume: 3,113 shs
• Market Capitalization: N/A
• P/E Ratio: 45.83
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Mayne Pharma Group Stock Analysis - MarketRank™

Mayne Pharma Group scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Mayne Pharma Group.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Mayne Pharma Group is 45.83, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 40.23.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mayne Pharma Group is 45.83, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 25.79.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Mayne Pharma Group has a short interest ratio ("days to cover") of 421.14, which indicates bearish sentiment.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mayne Pharma Group does not currently pay a dividend.

Dividend Growth

Mayne Pharma Group does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.61

News Sentiment

Mayne Pharma Group has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Mayne Pharma Group this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Mayne Pharma Group insiders have not sold or bought any company stock.

Percentage Held by Institutions

15.80% of the stock of Mayne Pharma Group is held by institutions.

Company Calendar

• Today: 6/30/2026
• Next Earnings (Estimated): 8/20/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - General
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:MAYNF
• CIK: N/A
• Web: www.maynepharma.com
• Phone: (188) 209-2666
• Fax: N/A
• Employees: 780
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 45.83
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A